Open-label, prospective evaluation of adalimumab for psoriasis patients who were nonresponders to etanercept

被引：0
|
作者：
Martyn-Simmons, C. [1 ]
Green, E. [1 ]
Ash, G. [1 ]
Groves, R. [1 ]
Smith, C. H. [1 ]
Barker, J. N. W. N. [1 ]
机构：
[1] St Johns Inst Dermatol, London, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2008年 / 159卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：1425 / 1426
页数：2
相关论文
共 50 条
  • [1] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation
    Martyn-Simmons, C. L.
    Green, L.
    Ash, G.
    Groves, R. W.
    Smith, C. H.
    Barker, J. N. W. N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (12) : 1394 - 1397
  • [2] Adalimumab is effective for psoriasis patients who are primary nonresponders to etanercept: Subanalysis of an open-label clinical trial
    Strober, Bruce
    Weisman, Jamie
    Okun, Martin
    Gu, Yihua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB8 - AB8
  • [3] Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab
    Bagel, J.
    Tyring, S.
    Rice, K. C.
    Collier, D. H.
    Kricorian, G.
    Chung, J.
    Iles, J.
    Stolshek, B. S.
    Kaliyaperumal, A.
    Papp, K. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (02) : 411 - 418
  • [4] An Open-Label, Prospective Cohort Pilot Study to Evaluate the Efficacy and Safety of Etanercept in the Treatment of Moderate to Severe Plaque Psoriasis in Patients Who Have Not Had an Adequate Response to Adalimumab
    Vender, Ronald
    JOURNAL OF DRUGS IN DERMATOLOGY, 2011, 10 (04) : 396 - 402
  • [5] The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study
    Gottlieb, Alice B.
    Kalb, Robert E.
    Blauvelt, Andrew
    Heffernan, Michael P.
    Sofen, Howard L.
    Ferris, Laura Korb
    Kerdel, Francisco A.
    Calabro, Stephen
    Wang, Jim
    Kerkmann, Urs
    Chevrier, Marc
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (04) : 642 - 650
  • [6] Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab
    Al-Mutairi, Nawaf
    Nour, Tarek
    Al-Rqobah, Duha
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (05) : 625 - 629
  • [7] An open-label study to evaluate the efficacy of retreatment of patients with psoriasis who have previously been treated with etanercept
    Vitiello, Magalys
    Abuchar, Adriana
    Grant, Annika
    Kerdel, Francisco
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB35 - AB35
  • [8] Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study
    Strober, Bruce E.
    Poulin, Yves
    Kerdel, Francisco A.
    Langley, Richard G.
    Gu, Yihua
    Gupta, Shiraz R.
    Okun, Martin M.
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (04) : 671 - 681
  • [9] Adalimumab treatment of psoriasis patients following suboptimal responses to etanercept, methotrexate, or phototherapy: Efficacy across subgroups in an open-label study
    Strober, B.
    Goldblum, O.
    Langley, R.
    Gu, Y.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB152 - AB152
  • [10] Adalimumab for severe palmoplantar psoriasis: An open-label pilot trial in nine patients
    Guimera-Martin-Neda, Francisco
    Rodriguez-Garcia, Cristina
    Perez-Robayna, Nuria
    Sanchez-Gonzalez, Rosalba
    Gonzalez, Sorahaya
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB158 - AB158
12345